201 related articles for article (PubMed ID: 36423871)
1. Polymer- and lipid-based gene delivery technology for CAR T cell therapy.
Pinto IS; Cordeiro RA; Faneca H
J Control Release; 2023 Jan; 353():196-215. PubMed ID: 36423871
[TBL] [Abstract][Full Text] [Related]
2. Biomaterials in Chimeric Antigen Receptor T-Cell Process Development.
Cardle II; Cheng EL; Jensen MC; Pun SH
Acc Chem Res; 2020 Sep; 53(9):1724-1738. PubMed ID: 32786336
[TBL] [Abstract][Full Text] [Related]
3. Nanotechnology and immunoengineering: How nanotechnology can boost CAR-T therapy.
Nawaz W; Xu S; Li Y; Huang B; Wu X; Wu Z
Acta Biomater; 2020 Jun; 109():21-36. PubMed ID: 32294554
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
[TBL] [Abstract][Full Text] [Related]
5. Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer.
Lundh S; Jung IY; Dimitri A; Vora A; Melenhorst JJ; Jadlowsky JK; Fraietta JA
Clin Exp Med; 2020 Nov; 20(4):469-480. PubMed ID: 32333215
[TBL] [Abstract][Full Text] [Related]
6. Non-viral transfection technologies for next-generation therapeutic T cell engineering.
Raes L; De Smedt SC; Raemdonck K; Braeckmans K
Biotechnol Adv; 2021; 49():107760. PubMed ID: 33932532
[TBL] [Abstract][Full Text] [Related]
7. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.
Mollanoori H; Shahraki H; Rahmati Y; Teimourian S
Hum Immunol; 2018 Dec; 79(12):876-882. PubMed ID: 30261221
[TBL] [Abstract][Full Text] [Related]
8. In Vitro Engineering Chimeric Antigen Receptor Macrophages and T Cells by Lipid Nanoparticle-Mediated mRNA Delivery.
Ye Z; Chen J; Zhao X; Li Y; Harmon J; Huang C; Chen J; Xu Q
ACS Biomater Sci Eng; 2022 Feb; 8(2):722-733. PubMed ID: 35104103
[TBL] [Abstract][Full Text] [Related]
9. Non-viral delivery of RNA for therapeutic T cell engineering.
Berdecka D; De Smedt SC; De Vos WH; Braeckmans K
Adv Drug Deliv Rev; 2024 May; 208():115215. PubMed ID: 38401848
[TBL] [Abstract][Full Text] [Related]
10. Expanding the horizon of transient CAR T therapeutics using virus-free technology.
Enriquez-Rodriguez L; Attia N; Gallego I; Mashal M; Maldonado I; Puras G; Pedraz JL
Biotechnol Adv; 2024; 72():108350. PubMed ID: 38537878
[TBL] [Abstract][Full Text] [Related]
11. [CAR-T cells immunotherapy in multiple myeloma: Present and future].
Ferment B; Arnulf B
Bull Cancer; 2021 Oct; 108(10S):S65-S72. PubMed ID: 34920809
[TBL] [Abstract][Full Text] [Related]
12. Self-Assembled Nanoparticles Prepared from Low-Molecular-Weight PEI and Low-Generation PAMAM for EGFRvIII-Chimeric Antigen Receptor Gene Loading and T-Cell Transient Modification.
Yu Q; Zhang M; Chen Y; Chen X; Shi S; Sun K; Ye R; Zheng Y; Chen Y; Xu Y; Peng J
Int J Nanomedicine; 2020; 15():483-495. PubMed ID: 32158206
[TBL] [Abstract][Full Text] [Related]
13. Chimeric antigen receptor T cell therapy in multiple myeloma: promise and challenges.
Dhakal B; Hari PN; Usmani SZ; Hamadani M
Bone Marrow Transplant; 2021 Jan; 56(1):9-19. PubMed ID: 32770147
[TBL] [Abstract][Full Text] [Related]
14. [Development of next-generation chimeric antigen receptor-engineered T-cell therapy].
Kagoya Y
Rinsho Ketsueki; 2022; 63(9):1290-1297. PubMed ID: 36198555
[TBL] [Abstract][Full Text] [Related]
15. Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity.
Yu S; Yi M; Qin S; Wu K
Mol Cancer; 2019 Aug; 18(1):125. PubMed ID: 31429760
[TBL] [Abstract][Full Text] [Related]
16. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
Gauthier J; Yakoub-Agha I
Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
[TBL] [Abstract][Full Text] [Related]
17. Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering.
Billingsley MM; Singh N; Ravikumar P; Zhang R; June CH; Mitchell MJ
Nano Lett; 2020 Mar; 20(3):1578-1589. PubMed ID: 31951421
[TBL] [Abstract][Full Text] [Related]
18. Generation of CAR-T cells using lentiviral vectors.
Poorebrahim M; Quiros-Fernandez I; Fakhr E; Cid-Arregui A
Methods Cell Biol; 2022; 167():39-69. PubMed ID: 35152998
[TBL] [Abstract][Full Text] [Related]
19. Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice.
Gajra A; Zalenski A; Sannareddy A; Jeune-Smith Y; Kapinos K; Kansagra A
Pharmaceut Med; 2022 Jun; 36(3):163-171. PubMed ID: 35672571
[TBL] [Abstract][Full Text] [Related]
20. Clinical data, limitations and perspectives on chimeric antigen receptor T-cell therapy in multiple myeloma.
Beauvais D; Danhof S; Hayden PJ; Einsele H; Yakoub-Agha I
Curr Opin Oncol; 2020 Sep; 32(5):418-426. PubMed ID: 32740095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
